The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat.

Journal

Canadian Urological Association journal = Journal de l'Association des urologues du Canada
ISSN: 1911-6470
Titre abrégé: Can Urol Assoc J
Pays: Canada
ID NLM: 101312644

Informations de publication

Date de publication:
Dec 2021
Historique:
pubmed: 26 6 2021
medline: 26 6 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

Prostate cancer is a significant cause of cancer mortality. It has been well-established that certain germline pathogenic variants confer both an increased risk of being diagnosed with prostate cancer and dying of prostate cancer.1 There are exciting developments in both the availability of genetic testing and opportunities for improved treatment of patients.On August 19, 2020, the Princess Margaret Cancer Centre in Toronto, Ontario, hosted a virtual retreat, bringing together international experts in urology, medical oncology, radiation oncology, medical genetics, and translational research, as well as a patient representative. We are pleased to provide this manuscript as a review of those proceedings for Canadian clinicians.We highlighted several needs for future research and policy action based on this meeting:Increased access to funding for germline testing for the common genetic disorders associated with increased risk of prostate cancer.More research into identifying genetic factors influencing risk stratification, treatment response, and outcomes of prostate cancer within Canadian populations at higher genetic risk for prostate cancer.Added awareness about genetic risk factors among the Canadian public.Development of patient-specific and reported outcomes research in tailored care for patients at increased genetic risk of prostate cancer.Creation of multidisciplinary clinics that specialize in tailored care for patients at increased genetic risk of prostate cancer.

Identifiants

DOI: 10.5489/cuaj.7383 PMID: 34171218 PMC: PMC8631832
pubmed: 34171218
pii: cuaj.7383
doi: 10.5489/cuaj.7383
pmc: PMC8631832
doi:

Types de publication

Journal Article

Langues

eng

Pagination

E623-E629

Références

Int J Clin Exp Med. 2015 Sep 15;8(9):15708-15
pubmed: 26629066
Cancer J Sci Am. 1998 Nov-Dec;4(6):385-9
pubmed: 9853138
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
Can Urol Assoc J. 2020 Apr;14(4):E137-E149
pubmed: 31702544
Eur Urol. 2020 Jan;77(1):24-35
pubmed: 31495749
Cancer. 2017 Sep 15;123(18):3532-3539
pubmed: 28608931
Can Urol Assoc J. 2017 Oct;11(10):298-309
pubmed: 29381452
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518089
J Genet Couns. 2016 Dec;25(6):1309-1316
pubmed: 27228984
Eur Urol. 2014 Sep;66(3):489-99
pubmed: 24484606
Nat Rev Genet. 2020 Sep;21(9):505-506
pubmed: 32601319
Cell. 1995 Sep 8;82(5):685-7
pubmed: 7671296
Annu Rev Genomics Hum Genet. 2017 Aug 31;18:201-227
pubmed: 28504904
J Clin Oncol. 2018 Feb 1;36(4):414-424
pubmed: 29236593
J Genet Couns. 2018 Feb;27(1):131-139
pubmed: 28780754
Br J Cancer. 2000 Nov;83(10):1301-8
pubmed: 11044354
Can Urol Assoc J. 2021 Feb;15(2):E90-E96
pubmed: 32853135
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
BJU Int. 2013 Sep;112(5):543-7
pubmed: 23924423
Prostate. 2019 Jun;79(8):880-895
pubmed: 30900310
Front Genet. 2020 Mar 04;11:127
pubmed: 32194621
Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28
pubmed: 24579667
Eur Urol. 2019 Dec;76(6):831-842
pubmed: 31537406
J Clin Oncol. 2005 Oct 20;23(30):7491-6
pubmed: 16234515
Am J Med Genet C Semin Med Genet. 2018 Mar;178(1):24-37
pubmed: 29512888
Eur Urol. 2014 Jan;65(1):169-76
pubmed: 22841674
J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7
pubmed: 11698567
JCO Oncol Pract. 2021 Feb;17(2):e204-e216
pubmed: 32970524
Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1
pubmed: 31171481
Cancer Manag Res. 2020 Sep 07;12:8105-8114
pubmed: 32982407
Eur Urol Oncol. 2020 Oct;3(5):594-611
pubmed: 32814685
J Genet Couns. 2013 Aug;22(4):411-21
pubmed: 23615968
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Sci Rep. 2016 Jul 13;6:29506
pubmed: 27406733
Nat Genet. 2015 Aug;47(8):906-10
pubmed: 26098866
Genet Med. 2020 Apr;22(4):727-735
pubmed: 31822848
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Br J Cancer. 2011 Oct 11;105(8):1230-4
pubmed: 21952622
Eur Urol. 2019 May;75(5):743-749
pubmed: 30309687

Auteurs

Roderick Clark (R)

Division of Urology, University Health Network, Toronto, ON, Canada.

Miran Kenk (M)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Kristen McAlpine (K)

Division of Urology, University Health Network, Toronto, ON, Canada.

Emily Thain (E)

Familial Cancer Clinic, University Health Network, Toronto, ON, Canada.

Kirsten M Farncombe (KM)

Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.

Colin C Pritchard (CC)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.

Robert Nussbaum (R)

Invitae Corporation, San Francisco, CA, United States.

Alexander W Wyatt (AW)

Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.

Johann de Bono (J)

Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom.

Danny Vesprini (D)

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Yvonne Bombard (Y)

Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada.

Justin Lorentz (J)

Genetics and High Risk Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Steven Narod (S)

Familial Breast Cancer Research Unit, Women's College Research Institute, Toronto, ON, Canada.

Raymond Kim (R)

Department of Medical Oncology, University Health Network, Toronto, ON, Canada.

Neil Fleshner (N)

Division of Urology, University Health Network, Toronto, ON, Canada.

Classifications MeSH